Stock Ratings / Health Care / MRKR / earnings

AEON (46) NEUP (31) RADX (46) PBM (46) ⌘ Pro Terminal →

Marker Therapeutics Inc. (MRKR) Next Earnings Date & Expected ±12.5% Move

$0.98 -2.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.97

Marker Therapeutics Inc. (MRKR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $16.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRKR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.98 (-2.97% 1D, market cap $16.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MRKR ranks #611 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MRKR compare to AEON and NEUP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRKR?

▼

Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $0 in revenue, -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.97 (-0.72%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRKR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY MRKR SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 45 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.92+26.1% Next Q

Q2 (-2Q)

Grade E$1.16-18.1% Next Q

Q3 (-1Q)

Grade E$0.95+3.2% Next Q

Current

Grade D-$0.98-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MRKR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MRKR currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($1.03) forces dealer call-delta covering toward $2.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRKR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MRKR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.12 Expected Swing

MODEL EARNINGS SETUP GAUGE

MRKR Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (35/100)Model Risk Weight (65/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$12.2M	-$12.0M	52%
FY 2024	2024-12-31	$0	-$10.7M	-$10.9M	52%
FY 2023	2023-12-31	$0	-$8.2M	-$16.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRKR)

✓Walkthrough of MRKR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MRKR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.18%▼ DESCENDING CHANNEL

2026-11-03O $1.01H $1.01L $0.98C $0.98VOL 67.6K

RES: $1.43SUP: $0.82SMA50: $1.13SMA200: $1.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRKR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MRKR Butterfly Map → + Track MRKR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MRKR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRKR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MRKR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRKR)

Health Care Rank #611 of 1016 ⚔️ AEON vs MRKR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MRKR vs. AEON, NEUP, RADX, PBM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Marker Therapeutics Inc. (MRKR) ranks #611 by composite RQD confidence (35/100, grade D-) and #845 by equity capitalization ($16.3M). Within this direct 5-issuer industry benchmark cohort, MRKR leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MRKR at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MRKR ACTIVE Marker Therapeutics Inc.	D-	35/100	—	—	-35.0%	-2.97%	$16.3M	Benchmark Subject
AEON AEON Biopharma Inc. (Class A)	D	46/100	—	—	-35.0%	-6.80%	$16.2M	/aeon-vs-mrkr →
NEUP Neuphoria Therapeutics Inc.	E	31/100	—	—	-11.8%	-0.33%	$16.5M	/neup-vs-mrkr →
RADX Radiopharm Theranostics Limited	D	46/100	—	—	—	-3.26%	$15.6M	/radx-vs-mrkr →
PBM Psyence Biomedical Ltd.	D	46/100	—	—	—	-8.31%	$17.6M	/pbm-vs-mrkr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001094038

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.2M, operating cash flow of -$12.0M, and free cash flow of -$12.0M (-10.1% YoY). On the balance sheet, MRKR closed FY2025 with $19.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.2M	-$12.0M	-$12.0M	$19.1M	—
FY2024 (FY)	2024-12-31	$0	-$10.7M	-$10.9M	-$10.9M	$22.0M	—
FY2023 (FY)	2023-12-31	$0	-$8.2M	-$16.4M	-$16.4M	—	—

3. MRKR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MRKR compare to AEON and NEUP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MRKR?

Where is MRKR trading relative to its 50-day, 200-day, and 52-week technical levels?

MRKR last traded at $0.98 (-2.97% on volume of 67,564 shares), positioning the stock -13.27% below its 50-day simple moving average ($1.13) and -27.94% below its 200-day simple moving average ($1.36). Across its 52-week range of $0.84 to $2.46, MRKR sits at the 8.6% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

MRKR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is MRKR's next earnings date?

Based on SEC filing cadence, Marker Therapeutics Inc. (MRKR)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MRKR stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for MRKR, spanning a range between $1 and $1.1.

Direct Sub-Reports: MRKR RQD Cockpit MRKR 12M Forecast MRKR Earnings & Move MRKR Dividends & DRIP MRKR Insiders & 13F MRKR Whale Options MRKR Profit Sankey MRKR News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MRKR — Marker Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MRKR scores 35 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (7/20): The rating cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this pillar signals that the business is not currently generating returns on invested capital or free cash flow. Any upside case must rest on future developments rather than present earnings power.
Whale 13F Flow (5/20): Institutional accumulation and options positioning are scored low. A weak institutional flow profile means less sponsorship behind the stock and a thinner base of large holders to support price during drawdowns.
Insider Conviction (5/20): SEC Form 4 and Congressional PTR cluster flow are scored low, indicating limited observable insider conviction in the source data.
Macro Regime Fit (8/20): Beta is 1.0 with sector sensitivity noted. The stock's market sensitivity is average, but the low score reflects weak alignment with the prevailing regime.
Forensic Balance Sheet (10/20): Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5 are cited. The Piotroski reading is weak, and the Altman figure sits in a zone that warrants caution.

Taken together, the scores point to a stock where downside risk is elevated relative to visible fundamental support. Valuation tradeoffs are difficult to assess given that earnings-based multiples are unavailable, so an investor would be relying on balance-sheet runway and speculative catalysts rather than cash generation. This is an analytical read of the rating, not personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-12.9M	$-12.2M	N/A	$-12.0M	$16.1M	N/A
FY 2024	$0.0M	$-11.1M	$-10.7M	N/A	$-10.9M	$19.2M	N/A
FY 2023	$0.0M	$-14.6M	$-8.2M	N/A	$-16.4M	N/A	N/A

Per the SEC financials, the company reported no revenue and continued operating losses across the three periods. Gross, operating, and net margins are each recorded at 0%, and ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited within the forensic balance-sheet pillar of the Roarable rating. Cash declined from $19.2M in FY 2024 to $16.1M in FY 2025, consistent with ongoing cash burn. Debt is reported as N/A in each period, and Debt/Equity is cited at 0.5.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items reference MRKR:

A Yahoo Finance report on a rating upgrade to Strong Buy (flagged GREEN, CATALYST).
A StockInvest.us price forecast piece (YELLOW, MARKET WIRE).
A Zacks Investment Research price and consensus chart (YELLOW, MARKET WIRE).
A Benzinga intraday health care movers report naming MRKR (YELLOW, MARKET WIRE).
A Traders Union live price and news page (YELLOW, MARKET WIRE).
A Syfe price and news page (YELLOW, MARKET WIRE).

The feed contains no specific clinical, regulatory, or financing events; the items are market-wire coverage. The single GREEN item is the headline reporting a rating upgrade, which is a third-party rating characterization rather than a company event. Per the Butterfly Supply-Chain Graph, no proprietary signals are present (supply_chain: NONE).

Open Questions

What are the company's specific product candidates, development stages, and next clinical or regulatory milestones?
What is the current cash runway given FY 2025 cash of $16.1M and a net loss of $-12.2M, and does the company hold any debt?
Which underlying events drove the upgrade headline cited in the news feed, and is it tied to a company development?
What are the reported EPS and valuation multiples, which are currently unavailable in the source data?
What institutional, insider, and analyst coverage exists, given that holders and analyst data are both NONE?

MRKR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Marker Therapeutics Inc. (MRKR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MRKR Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 17h ago

All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy

Yahoo Finance report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 20h ago

Marker Therapeutics Stock Price Forecast. Should You Buy MRKR?

StockInvest.us report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Zacks Investment Research • 23h ago

MRKR: MARKER THERAPEUTICS - Price & Consenus Chart

Zacks Investment Research report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th

Benzinga report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Marker Therapeutics, Inc. Stock Price Today | MRKR Live Chart & News

Traders Union report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

Marker Therapeutics, Inc. (MRKR) Stock Price & News

Syfe report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

MRKR Q3'26 Earnings: revenue estimate is 2.12M USD

TradingView report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Marker Therapeutics Awarded $2.6 Million FDA Orphan

GlobeNewswire report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRKR Bull vs. Bear Conversation Board — What's Your Call at $0.98?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRKR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.89 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MRKR (D- • RQD 35/100) a Buy at $1.01?

Welcome to the MRKR (Marker Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.80 (-20.8%)

Spot @ $1.01

Pump the brakes on MRKR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MRKR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Marker Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.25 (+23.8%)

Spot @ $1.01

MRKR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MRKR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.01 (52-wk range $0.84 - $2.46), any beat on forward guidance forces shorts and underweight funds to chase.